Efficacy and Safety of ATO Plus ATRA in Nucleophosmin-1 Mutated Acute Myeloid Leukemia

PHASE1/PHASE2Enrolling by invitationINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 8, 2017

Primary Completion Date

May 15, 2026

Study Completion Date

October 15, 2027

Conditions

AML

Interventions

DRUG

Cytarabine

Cytarabine at a dose of 3g/㎡/d on the first, third and fifth day.

DRUG

all-trans retinoic acid

ATRA at a dose of 30mg/㎡/d on day 1-14.

DRUG

Arsenic Trioxide

ATO at a dose of 10mg/d on day 1-14

Trial Locations (1)

Institute of Hematology & Blood Diseases Hospital, Tianjin

All Listed Sponsors

lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER